Trial · NCT03067441
Results by group111
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 111
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo; Bempedoic Acid | Participants with TEAEs | 385 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempedoic Acid; Bempedoic Acid | Participants with TEAEs | 758 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | OLE Bempedoic Acid | Participants with TEAEs | 1143 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo; Bempedoic Acid | Participants with serious TEAEs | 97 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempedoic Acid; Bempedoic Acid | Participants with serious TEAEs | 202 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | OLE Bempedoic Acid | Participants with serious TEAEs | 299 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo; Bempedoic Acid | Participants with TEAEs of mild severity | 93 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempedoic Acid; Bempedoic Acid | Participants with TEAEs of mild severity | 195 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | OLE Bempedoic Acid | Participants with TEAEs of mild severity | 288 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo; Bempedoic Acid | Participants with TEAEs of moderate severity | 211 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempedoic Acid; Bempedoic Acid | Participants with TEAEs of moderate severity | 403 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | OLE Bempedoic Acid | Participants with TEAEs of moderate severity | 614 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo; Bempedoic Acid | Participants with TEAEs of severe severity | 81 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempedoic Acid; Bempedoic Acid | Participants with TEAEs of severe severity | 160 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | OLE Bempedoic Acid | Participants with TEAEs of severe severity | 241 | Participants | |
| Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78 | Placebo; Bempedoic Acid | Week 52 | -12.82 | Standard Deviation 23.419 | percent change |
| Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78 | Bempedoic Acid; Bempedoic Acid | Week 52 | -13.80 | Standard Deviation 25.018 | percent change |
| Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78 | OLE Bempedoic Acid | Week 52 | -13.47 | Standard Deviation 24.485 | percent change |
| Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78 | Placebo; Bempedoic Acid | Week 78 | -14.99 | Standard Deviation 23.660 | percent change |
| Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78 | Bempedoic Acid; Bempedoic Acid | Week 78 | -14.15 | Standard Deviation 25.113 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03067441/results